Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
IMMURON stock logo
IMRN
IMMURON
$1.73
-13.8%
$5.04
$1.50
$2.87
$10.94M0.8263,368 shs12,391 shs
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
$0.92
-6.5%
$0.98
$0.81
$3.02
$36.84M2.791.08 million shs1.77 million shs
Nephros Inc. stock logo
NEPH
Nephros
$3.65
+1.8%
$3.37
$1.36
$5.00
$38.65M1.0918,587 shs17,260 shs
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
$0.41
-1.2%
$0.57
$0.39
$3.85
$25.85M-0.021.15 million shs930,843 shs
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
IMMURON stock logo
IMRN
IMMURON
-2.13%+3.95%+6.11%+2.56%-30.04%
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
+1.03%-9.26%0.00%-9.26%-24.03%
Nephros Inc. stock logo
NEPH
Nephros
+3.77%-4.53%-5.29%+82.75%+65.74%
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
+1.68%-36.86%-18.88%-64.37%-88.73%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
IMMURON stock logo
IMRN
IMMURON
1.491 of 5 stars
3.53.00.00.01.10.00.0
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
2.0815 of 5 stars
3.53.00.00.03.30.00.0
Nephros Inc. stock logo
NEPH
Nephros
2.8037 of 5 stars
3.55.00.00.02.70.80.0
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
2.3444 of 5 stars
3.51.00.00.03.11.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
IMMURON stock logo
IMRN
IMMURON
3.00
Buy$5.00189.86% Upside
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
3.00
Buy$9.00882.53% Upside
Nephros Inc. stock logo
NEPH
Nephros
3.00
Buy$5.0037.14% Upside
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
3.00
Buy$7.331,679.94% Upside

Current Analyst Ratings Breakdown

Latest IMRN, RANI, NEPH, and ITRM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/16/2025
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$14.00 ➝ $4.00
5/8/2025
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$9.00
(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
IMMURON stock logo
IMRN
IMMURON
$3.21M3.14N/AN/A$1.46 per share1.18
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
N/AN/AN/AN/A($0.15) per shareN/A
Nephros Inc. stock logo
NEPH
Nephros
$14.16M2.73$0.02 per share172.41$0.81 per share4.50
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
$1.03M25.28N/AN/A$0.06 per share6.87
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
IMMURON stock logo
IMRN
IMMURON
-$4.55MN/A0.00N/AN/AN/AN/AN/AN/A
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
-$24.77M-$0.99N/AN/AN/AN/A-71.37%8/13/2025 (Estimated)
Nephros Inc. stock logo
NEPH
Nephros
$70K$0.0752.09N/A5.16%9.43%7.20%8/6/2025 (Estimated)
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
-$30.02M-$0.99N/AN/AN/AN/A-1,258.76%-80.52%8/5/2025 (Estimated)

Latest IMRN, RANI, NEPH, and ITRM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
-$0.13N/AN/AN/AN/AN/A
8/5/2025Q2 2025
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
-$0.19N/AN/AN/AN/AN/A
5/15/2025Q1 2025
Nephros Inc. stock logo
NEPH
Nephros
-$0.0050$0.0526+$0.0576$0.05$3.67 million$4.88 million
5/13/2025Q1 2025
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
-$0.14-$0.14N/A-$0.14N/AN/A
5/13/2025Q1 2025
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
-$0.22-$0.22N/A-$0.22N/A$0.20 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
IMMURON stock logo
IMRN
IMMURON
N/AN/AN/AN/AN/A
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
N/AN/AN/AN/AN/A
Nephros Inc. stock logo
NEPH
Nephros
N/AN/AN/AN/AN/A
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
IMMURON stock logo
IMRN
IMMURON
N/A
6.80
5.92
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
N/A
3.72
3.58
Nephros Inc. stock logo
NEPH
Nephros
N/A
5.92
4.64
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
2.75
0.88
0.88

Institutional Ownership

CompanyInstitutional Ownership
IMMURON stock logo
IMRN
IMMURON
0.12%
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
9.21%
Nephros Inc. stock logo
NEPH
Nephros
41.10%
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
30.19%

Insider Ownership

CompanyInsider Ownership
IMMURON stock logo
IMRN
IMMURON
7.01%
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
9.20%
Nephros Inc. stock logo
NEPH
Nephros
6.70%
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
45.08%
CompanyEmployeesShares OutstandingFree FloatOptionable
IMMURON stock logo
IMRN
IMMURON
N/A5.85 million5.44 millionNot Optionable
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
1040.00 million36.32 millionNot Optionable
Nephros Inc. stock logo
NEPH
Nephros
3010.60 million9.89 millionNot Optionable
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
11063.21 million34.71 millionOptionable

Recent News About These Companies

Rani Therapeutics (NASDAQ:RANI) Shares Up 8.4% - Here's What Happened
Rani Therapeutics strikes deal to issue new warrants
RANI: 1Q:25 Financial Results
Stifel Nicolaus Remains a Buy on Trevi Therapeutics (TRVI)
Rani Therapeutics management to meet virtually with Lake Street
RANI: 2024 Financial Results
Q4 2024 Rani Therapeutics Holdings Inc Earnings Call
Rani Therapeutics reports Q4 EPS (27c), consensus (23c)

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMMURON stock logo

IMMURON NASDAQ:IMRN

Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia.

Iterum Therapeutics stock logo

Iterum Therapeutics NASDAQ:ITRM

$0.92 -0.06 (-6.43%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Nephros stock logo

Nephros NASDAQ:NEPH

$3.64 +0.07 (+1.82%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also manufactures and sells water filters that enhance the taste and odor of water, as well as reduce biofilm, cysts, particulates, and scale build-up in downstream equipment. It markets its products to food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.

Rani Therapeutics stock logo

Rani Therapeutics NASDAQ:RANI

$0.41 0.00 (-0.94%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.